| ²é¿´: 1472 | »Ø¸´: 4 | ||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | ||
sophielajľ³æ (СÓÐÃûÆø)
|
[ÇóÖú]
ŵ»ªÎªÊ²Ã´ÔÚÃÀ¹úÍ£Ö¹ÏúÊÛ¸ñÁÐÎÀ½ºÄÒ¼Á£¿
|
|
ÈçÌâ¡¡![]() ![]() ![]() ÕÒÁË´ó°ëÌ죬ÕÒµ½Ò»Ìõ¿´ËÆÓÐÓÃȴûÓõÄÐÅÏ¢£º Hyman, Phelps & McNamara, PC, submitted a citizen petition dated June 3, 2010 (Docket No. FDA¨C2010¨CP¨C0275), under 21 CFR 10.30, requesting that the Agency determine whether GLEEVEC (imatinib mesylate) Capsules, 50 mg and 100 mg, were withdrawn from sale for reasons of safety or effectiveness. After considering the citizen petition and reviewing Agency records, FDA has determined under ¡ì 314.161 that GLEEVEC (imatinib mesylate) Capsules, 50 mg and 100 mg were not withdrawn for reasons of safety or effectiveness. £¨ÃÀ¹úÁª°î¹«±¨£¨2010-12-7£©£© |
» ²ÂÄãϲ»¶
Ò©ÎïѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ183È˻ظ´
sophielaj
ľ³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 3995.6
- ºì»¨: 1
- Ìû×Ó: 53
- ÔÚÏß: 93Сʱ
- ³æºÅ: 602326
- ×¢²á: 2008-09-14
- ÐÔ±ð: MM
- רҵ: ÉúÎï¼¼ÊõÒ©Îï
3Â¥2013-09-11 09:00:57
wnting
ÖÁ×ðľ³æ (ÕýʽдÊÖ)
- Ó¦Öú: 1 (Ó×¶ùÔ°)
- ½ð±Ò: 12556.2
- Ìû×Ó: 340
- ÔÚÏß: 119.1Сʱ
- ³æºÅ: 423361
- ×¢²á: 2007-07-21
- ÐÔ±ð: GG
- רҵ: ÁÙ´²Ò©Àí
2Â¥2013-09-10 13:59:17
wnting
ÖÁ×ðľ³æ (ÕýʽдÊÖ)
- Ó¦Öú: 1 (Ó×¶ùÔ°)
- ½ð±Ò: 12556.2
- Ìû×Ó: 340
- ÔÚÏß: 119.1Сʱ
- ³æºÅ: 423361
- ×¢²á: 2007-07-21
- ÐÔ±ð: GG
- רҵ: ÁÙ´²Ò©Àí
4Â¥2013-09-11 16:30:45
sophielaj
ľ³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 3995.6
- ºì»¨: 1
- Ìû×Ó: 53
- ÔÚÏß: 93Сʱ
- ³æºÅ: 602326
- ×¢²á: 2008-09-14
- ÐÔ±ð: MM
- רҵ: ÉúÎï¼¼ÊõÒ©Îï
5Â¥2013-09-12 16:27:13














»Ø¸´´ËÂ¥